†† Information not included in package insert. Although ccIIV4 viruses are propagated in mammalian cells rather than in eggs, one of the four initial viruses supplied to the manufacturer is egg derived (for 2018 preference is expressed for any influenza vaccine product. ACIP will continue to review data concerning the effectiveness of LAIV4 as they become available.

4. Once the stopper of the multi-dose vial is pierced the vial must be discarded within 28 days.

6. Fluad® includes the MF59C.1 adjuvant (MF59®), a squalene based oil-in-water emulsion.

5. Afluria® is licensed for administration by PharmaJet® Stratis® Needle-Free Injection System for persons aged 18 through 64 years only.

7. Trivalent inactivated vaccine high-dose: a 0.5-mL dose contains 60 µg of each vaccine antigen (180 µg total).

8. Recommendation of the CDC’s Advisory Committee on Immunization Practices (ACIP) for the 2018-19 influenza season, providers may choose to administer any licensed, age-appropriate influenza vaccine (IIV, recombinant influenza vaccine (RIV), or LAIV4). LAIV4 (FluMist®) is an option for those for whom it is otherwise appropriate. In addition, LAIV4 is acceptable for persons with a history of egg allergy. No preference is expressed for any influenza vaccine product. ACIP will continue to review data concerning the effectiveness of LAIV4 as they become available.

†† Information not included in package insert. Although cclIV4 viruses are propagated in mammalian cells rather than in eggs, one of the four initial viruses supplied to the manufacturer is egg derived (for 2018, the H1N1 is still egg derived), so not considered egg-free.

§§ Available upon request from Sanofi Pasteur (1-800-822-2463 or MIS.emails@sanofipasteur.com).

* Direct Vendor Delivery (DVD) vaccines are available for purchase by Medical Treatment Facilities. Refer to the 2018-2019 Seasonal Influenza DHA-IPM for information on the ordering process.